A Case Report Overwhelming response to TNF-alfa inhibitor Infliximab “innovator” Vs. Adalimumab “Bio-similar” in a previously therapy naive adult. (2022). Indian Journal of Case Reports, 8(3), 58-61. https://doi.org/10.32677/ijcr.v8i3.3317